These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 10734314)

  • 41. Silencing the MET oncogene leads to regression of experimental tumors and metastases.
    Corso S; Migliore C; Ghiso E; De Rosa G; Comoglio PM; Giordano S
    Oncogene; 2008 Jan; 27(5):684-93. PubMed ID: 17684486
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma.
    Kim CH; Moon SK; Bae JH; Lee JH; Han JH; Kim K; Choi EC
    Acta Otolaryngol; 2006 Jan; 126(1):88-94. PubMed ID: 16308260
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Progression of head and neck squamous cell cancer.
    Tímár J; Csuka O; Remenár E; Répássy G; Kásler M
    Cancer Metastasis Rev; 2005 Jan; 24(1):107-27. PubMed ID: 15785876
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expression of insulin-like growth factor-2, c-MET, matrix metalloproteinase-7 and MUC-1 in primary lesions and lymph node metastatic lesions of gastric cancer.
    Ajisaka H; Fushida S; Yonemura Y; Miwa K
    Hepatogastroenterology; 2001; 48(42):1788-92. PubMed ID: 11813625
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Persistent activation of Rac1 in squamous carcinomas of the head and neck: evidence for an EGFR/Vav2 signaling axis involved in cell invasion.
    Patel V; Rosenfeldt HM; Lyons R; Servitja JM; Bustelo XR; Siroff M; Gutkind JS
    Carcinogenesis; 2007 Jun; 28(6):1145-52. PubMed ID: 17234718
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
    MacDougall CA; Vargas M; Soares CR; Holzer RG; Ide AE; Jorcyk CL
    Prostate; 2005 Jul; 64(2):139-48. PubMed ID: 15678502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Met proto-oncogene and insulin-like growth factor binding protein 3 overexpression correlates with metastatic ability in well-differentiated pancreatic endocrine neoplasms.
    Hansel DE; Rahman A; House M; Ashfaq R; Berg K; Yeo CJ; Maitra A
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6152-8. PubMed ID: 15448002
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene.
    Schmidt L; Junker K; Weirich G; Glenn G; Choyke P; Lubensky I; Zhuang Z; Jeffers M; Vande Woude G; Neumann H; Walther M; Linehan WM; Zbar B
    Cancer Res; 1998 Apr; 58(8):1719-22. PubMed ID: 9563489
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas.
    Zhuang Z; Park WS; Pack S; Schmidt L; Vortmeyer AO; Pak E; Pham T; Weil RJ; Candidus S; Lubensky IA; Linehan WM; Zbar B; Weirich G
    Nat Genet; 1998 Sep; 20(1):66-9. PubMed ID: 9731534
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting the MET oncogene in cancer and metastases.
    Stella GM; Benvenuti S; Comoglio PM
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A common MET polymorphism harnesses HER2 signaling to drive aggressive squamous cell carcinoma.
    Kong LR; Mohamed Salleh NAB; Ong RW; Tan TZ; Syn NL; Goh RM; Fhu CW; Tan DSW; Iyer NG; Kannan S; Verma CS; Lim YC; Soo R; Ho J; Huang Y; Lim JSJ; Yan BJ; Nga ME; Lim SG; Koeffler HP; Lee SC; Kappei D; Hung HT; Goh BC
    Nat Commun; 2020 Mar; 11(1):1556. PubMed ID: 32214092
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Understanding c-MET signalling in squamous cell carcinoma of the head & neck.
    Szturz P; Raymond E; Abitbol C; Albert S; de Gramont A; Faivre S
    Crit Rev Oncol Hematol; 2017 Mar; 111():39-51. PubMed ID: 28259294
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel mutation in the ATP-binding site of the MET oncogene tyrosine kinase in a HPRCC family.
    Olivero M; Valente G; Bardelli A; Longati P; Ferrero N; Cracco C; Terrone C; Rocca-Rossetti S; Comoglio PM; Di Renzo MF
    Int J Cancer; 1999 Aug; 82(5):640-3. PubMed ID: 10417759
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A point mutation in the MET oncogene abrogates metastasis without affecting transformation.
    Giordano S; Bardelli A; Zhen Z; Menard S; Ponzetto C; Comoglio PM
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13868-72. PubMed ID: 9391119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. iPSC-Derived Embryoid Bodies as Models of c-
    Hwang JW; Desterke C; Féraud O; Richard S; Ferlicot S; Verkarre V; Patard JJ; Loisel-Duwattez J; Foudi A; Griscelli F; Bennaceur-Griscelli A; Turhan AG
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31575031
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Different point mutations in the met oncogene elicit distinct biological properties.
    Giordano S; Maffe A; Williams TA; Artigiani S; Gual P; Bardelli A; Basilico C; Michieli P; Comoglio PM
    FASEB J; 2000 Feb; 14(2):399-406. PubMed ID: 10657996
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A mouse model of activating Met mutations.
    Graveel CR; London CA; Vande Woude GF
    Cell Cycle; 2005 Apr; 4(4):518-20. PubMed ID: 15738649
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy.
    Comoglio PM; Trusolino L; Boccaccio C
    Nat Rev Cancer; 2018 Jun; 18(6):341-358. PubMed ID: 29674709
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Absence of ALK and MET alterations in head and neck sarcomatoid carcinoma.
    Perrone F; Bossi P; Cortelazzi B; Dagrada GP; Paielli N; Licitra L; Pilotti S
    Oral Oncol; 2016 Jul; 58():e4-5. PubMed ID: 27262592
    [No Abstract]   [Full Text] [Related]  

  • 60. MET Activation and Physical Dynamics of the Metastatic Process: The Paradigm of Cancers of Unknown Primary Origin.
    Stella GM; Benvenuti S; Gentile A; Comoglio PM
    EBioMedicine; 2017 Oct; 24():34-42. PubMed ID: 29037604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.